UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

June 30, 2022

Commission File Number: 001-39363

IMMATICS N.V.

Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 \times

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): 🗆

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): 🗆

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On June 30, 2022, Immatics N.V. (the "Company") made available an updated investor presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.1. The fact that the presentation is being made available and furnished herewith is not an admission as to the materiality of any information contained in the presentation. The information contained in the presentation is being provided as of June 30, 2022 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.

Exhibit No.Description99.1Corporate presentation dated June 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMMATICS N.V.

By: Name: Title: /s/ Harpreet Singh Harpreet Singh Chief Executive Officer

Date: June 30, 2022





Immatics Corporate Presentation June 30, 2022

© Immatics. Not for further reproduction or distribution.

Forward-Looking Statements



This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

Forward-Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the clinical trial application for IMA204, IMA301, IMA401, the Company's focus on partnerships to advance its strategy, projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "pelieve", "product", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company's fillings with the Securities and Exchange Commission (the "SEC"). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements which speak only as of the date they are made. Company undertakes no duty to update these forward-looking statements.

No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. Clinical study results and associated biomarker studies presented within this presentation are by definition prior to completion of the clinical trial and a clinical study report and, are therefore, preliminary in nature and subject to further quality checks including customary source data verification. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

Building a Leading TCR Therapeutics Company

Immatics



Two Clinical-Stage Modalities

Pipeline of TCR-T and TCR Bispecific product candidates in clinical & preclinical development



Clinical PoC for Cell Therapy

Objective responses across multiple solid tumors in early TCR-T clinical development



Differentiated Platforms

Unique technologies to identify true cancer targets and right TCRs



Therapeutic Opportunity

Potential for addressing large patient populations with high prevalence targets in solid tumors



Strategic Partnerships

World-leading industry players with synergistic expertise




Solid Cash Runway

To reach next value inflections points across our portfolio




Our TCR-based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface



Two Distinct TCR-based Therapeutic Modalities in Clinical Development





Differentiated positioning of ACTengine® vs. TCER® based on patient population, medical need and geographical reach

Intro ¹ Interim dose escalation data from the IMA203 Phase 1a trial with an objective response rate of 50% (8/16) across several solid tumor indications; ² Repeat dosing without re-manufacturing possible 5

Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics

Modality	Product Candidate	Target		Preclinical	Phase 1a ¹	Phase 1b ¹	Phase 2/3
	IMA203	PRAME	immatics	+ Ch	eckpoint Inhibitor ²		
ACTengine® Autologous ACT	IMA203CD8	PRAME	immatics				
	IMA201	MAGEA4/8	Immatics				
	IMA204	COL6A3	immatics				
Autologous ACT	4 programs	Undisclosed	🐴 Bristol Myers Squibb'				
	2 programs	Undisclosed	GSK				
ACTallo®	IMA30x	Undisclosed	immatics				
Allogeneic ACT γδ T cells	2 programs	Undisclosed	🕅 Bristol Myers Squibb'				
	IMA401	MAGEA4/8	(⁴⁾ Bristol Myers Squibb'				
TCER [®] Bispecifics	IMA402	PRAME	immatics				
	IMA40x	Undisclosed	immatics				
Bispecifics	3 programs	Undisclosed	Genmab				

Intro


¹Phase 1a: Dose escalation, Phase 1b: Dose expansion; ² Opdivo⁹ (nivolumab): programmed death-1 (PD-1) immune checkpoint inhib

1000

Immatics


Strategic Collaborations

Synergistic Expertise that Can Foster Transformative Innovations for ACT and Bispecifics



Immatics

Immatics and Bristol Myers Squibb – New Allogeneic Multi-program Collaboration Leveraging Complementary Technologies & Capabilities for the Benefit of Cancer Patients



Potential for Large Patient Populations across Multiple Solid Cancers

	IMA201 / IMA401	IMA203 / IMA402	IMA204
	MAGEA4/8	PRAME	COL6A3 exon 6
Selected solid cancer indications with significant target prevalence ¹	Sarcoma Subtypes – up to 80% Squamous NSCLC – 50% HNSCC – 35% Bladder Carcinoma – 30% Esophageal Carcinoma – 25% Uterine Carcinosarcoma – 25% Ovarian Carcinoma – 20% Melanoma – 20%	Uterine Carcinoma – 100% Sarcoma Subtypes – up to 100% Melanoma – 95% Uveal Melanoma – 80% ² Ovarian Carcinoma – 80% Squamous NSCLC – 65% Kidney Carcinoma – up to 45% Cholangiocarcinoma – 35% Adeno NSCLC – 25% Breast Carcinoma – 25% HNSCC – 25% Esophageal Carcinoma – 20% HCC – 20% Bladder Carcinoma – 20%	Pancreatic Carcinoma – 80% Breast Carcinoma – 75% Stomach Carcinoma – 65% Sarcoma – 65% Esophageal Carcinoma – 60% Squamous NSCLC– 55% Adeno NSCLC– 55% HNSCC – 55% Uterine Carcinosarcoma – 55% Colorectal Carcinoma – 45% Mesothelioma – 45% Cholangiocarcinoma – 40% Ovarian Carcinoma – 40% Melanoma – 35% Bladder Carcinoma – 35%

ACTengine® and TCER® targets demonstrate high expression in multiple solid cancers

for selected cancer indications based on mRNA expression (TCGA and Immatics inhouse data);

¹ Solid ca ² Based o





ACTengine® IMA203 – TCR-T Targeting PRAME

ACTengine® IMA203 – TCR-T Targeting PRAME

Broadly Expressed Target on Multiple Solid Cancers Combined with Highly Specific TCR

ARGET

HLA-A*02-presented peptide derived from **PRAME**

Naturally and specifically presented on tumors at high target density¹: **100-1,000 copies/cell**

Identified and validated by XPRESIDENT[®] quant. mass spectrometry platform

IMA203

TCR

High-affinity, specific TCR targeting PRAME

Pairing-enhanced, engineered TCR to avoid mispairing

High functional avidity²: EC50 ~5 ng/ml

Identified and characterized by XCEPTOR® TCR discovery and engineering platform

CLINICAL DATA

N=18 pts treated in phase 1 dose escalation cohort

Manageable tolerability profile; no additional DLTs³ & no CRS/ICANS ≥ grade 3

16 patients with at least one post treatment tumor assessment


Objective responses in 50% (8/16) of patients, thereof 62% (8/13) of responses above DL1; all doses still below 1 bn cells

PATIENT POPULATION⁴

Uterine Carcinoma – 100% Sarcoma Subtypes – up to 100% Melanoma – 95% Uveal Melanoma – 80%⁵ Ovarian Carcinoma – 80% Squamous NSCLC – 65% Kidney Carcinoma – up to 45% Cholangiocarcinoma – 35% Adeno NSCLC – 25% Breast Carcinoma – 25% HNSCC – 25% Esophageal Carcinoma – 20% HCC – 20%

ACTengine® IMA203 Targeting PRAME – Mechanism of Action

Immatics' Leading TCR-T Approach



Immatics


Optimized Cell Therapy Products to Enhance T cell Persistence & Efficacy

Current Proprietary Manufacturing Protocol for ACTengine® Product Candidates

Leukapheresis

Infusion-Ready

immatics



Proprietary Manufacturing Process, designed to


- reduce manufacturing process to approx. 1 week¹
- ✓ shorten vein-to-vein time
- ✓ generate younger T cells with increased proliferative capacity
- improve engraftment and persistence in patients while utilizing smaller doses

In-house state-of-the-art cGMP Facility²

- Manufacturing by Immatics personnel
- Maximum capacity: 48 manufacturing runs/month
- Substantial in-house process development expertise

ACTengine® IMA203: 7 days, IMA201: 7-10 days; ² Exclusive access through collaboration with UT Health, Houston, TX

ACTengine[®] IMA203 – Patient Flow




ACTengine® IMA203 – Key Objectives & Trial Design

Presented at SITC Conference as Late-Breaking Presentation (Cut-off October 05, 2021)

Key Study Objectives

Trial Design & Recruitment Status



18 patients¹ infused with PRAME-directed T cells at 5 clinical sites

Data cut-off – 05-Oct-2021

IMA203 ¹Enrichment cohorts EC1 & EC2: patients infused with intermediate doses enabling infusion of patients with medical need during dose escalation observation periods, or in case of lower production yields; * One patient infused at the same dose level as part of the enrichment cohort; **Dose is shown as transduced viable CD8 T cells per m² total body surface area 15

ACTengine® IMA203 – Safety Profile

Manageable & Transient Treatment-emergent Adverse Events – No ≥ Grade 3 CRS or ICANS

			All grades		ade 3		All grades		≥ Grade 3		
	Adverse event	No.	%	No.	%	Adverse event	No.	%	No.	%	
	Patients with any adverse event	19	100.0	19	100.0	table continued					
and have a						Cardiac or vascular disorders					DLT:
CRS/ICANS:	Adverse Events of Special interest						3	15.8	2	10.5	Transient, Gra
io ≥ Grade 3 CRS	Cytokine release syndrome	17	89.5	0	0.0	Hypertension Atrial fibrillation	2	10.5	2 14	10.5	atrial fibrillat
or ICANS	ICANS ²	4	21.1	0	0.0	Atrial Infiliation	2	10.5	1	5.5 <u> </u>	Onset on day 5
observed so far	Blood and lymphatic system disorders					General disorders and administration site	conditions				infusion that
	Neutropenia*	16	84.2	15	78.9	Fatigue	7	36.8	1	5.3	resolved within
	Anaemia	16	84.2	9	47.4	Pyrexia	5	26.3	0	0.0	
	Thrombocytopenia	15	78.9	7	36.8	Oedema peripheral	3	15.8	0	0.0	DLT triggere
Most Adverse	Lymphopenia*	14	73.7	14	73.7	Gastrointestinal disorders					expansion of
Events were	Leukopenia*	12	63.2	11	57.9	Nausea	12	63.2	0	0.0	
	Cytopenia	1	5.3	1	5.3	Vomiting	7	36.8	ō	0.0	
associated with	Infections and infestations					Diarrhoea	7	36.8	ō	0.0	
mphodepletion	Enterococcal infection		5.3			Constipation	6	31.6	0	0.0	
		1	5.3	1	5.3						
	COVID-19	1		1	5.3	Investigations Aspartate aminotransferase increased	5	26.3	0	0.0	
	Appendicitis	1	5.3	1	5.3	Alanine aminotransferase increased	2		0	0.0	
	Sepsis ³	1	5.3	1	5.3	Blood creatinine increased	4	21.1 21.1	0	0.0	
	Respiratory, thoracic and mediastinal disorders						4	21.1	U	0.0	
	Hypoxia	2	10.5	1	5.3	Other					
	Pleural effusion	2	10.5	1	5.3	Rash	5	26.3	0	0.0	
	Bronchial obstruction	1	5.3	1	5.3	Myalgia	4	21.1	0	0.0	
	Metabolism and nutrition disorders					Arthralgia	3	15.8	0	0.0	
		-	26.0			Alopecia	3	15.8	0	0.0	
	Hyponatraemia	1	36.8	1	5.3	Rash maculo-papular	2	10.5	1	5.3	
	Hypokalaemia Decreased appetite	5	26.3 15.8	1	5.3 0.0	Orchitis Contrast media allergy	1	5.3 5.3	1	5.3 5.3	


¹ All treatment-emergent adverse events (TEAEs) with grade 1-2 occurring in at least 3 patients (incidence ≥15.8%) and additionally all events with grade 3-5 regardless of relatedness to study treatment are presented. Data source: clinical database. Adverse events were coded using the Medical Dictionary for Regulatory Activities. Grades were determined according to National Cancer Institute Common Terminology Criteria of Adverse Events (TCAE), version 5.0. Grades for Cytokine release syndrome and ICANS were determined according to CARTOX criteria (Neelapu *et al.*, 2018). Patients are counted only once per adverse event and severity classification; ² ICANS: Immune effector cell-associated neurotoxicity syndrome; ³ Patient died from sepsis of unknown origin and did not receive IMA203 T cells; ⁴ DLT: Dose limiting toxicity; *100% of patients experienced transient cytopenias ≥ Grade 3 (CTCAE v5.0) Data cut-off = 05-Oct-202

IMA203

Immatics


ACTengine® IMA203 – Change in Target Lesions

Objective Responses across Multiple Tumor Types at Doses below 1 billion Transduced Cells



ACTengine® IMA203 – Response Over Time


Objective Responses across Multiple Tumor Types at Doses below 1 billion Transduced Cells



ACTengine® IMA203 – Engraftment, Persistence & Tumor Infiltration


Clinical Responses Consistent with Biological Data

T cell Engraftment & Persistence



High T cell engraftment and persistence with trend for association of peak vector copies with clinical response¹

Tumor Infiltration post Infusion²




High T cell infiltration observed through serial biopsies associated with clinical response³

Data cut-off - 05-Oct-2021

ACTengine® IMA203 – Case Study Patient IMA203-DL3-01

Confirmed Partial Response with Deepening Tumor Regression in Multiple Lesions



immatics

Objective responses observed across multiple tumor types at dose levels below 1 billion T cells originally presumed to be subtherapeutic


Immatics

SAFETY		CLINIC		BIOLOGICAL ACTIVITY		
3	Dose levels completed, all below 1 bn cells	50%	ORR ³ across all doses and multiple solid cancers	Blood	High T cell engraftment and persistence	
0	Additional DLTs ¹		(8/16 patients)			
0	Grade ≥3 CRS or ICANS ²	62%	ORR ³ at DL2 [*] & DL3 (8/13 patients) – all still dosed below 1 bn cells	Tumor	High T cell infiltration associated with clinical response	
					Data cut-off – 05-Oct-2	

Our Plans to Achieve Long-Lasting Responses with TCR-T cells against PRAME




Addressing Relevant Secondary Resistance Mechanisms to Increase Durability of Response



ACTengine® IMA203CD8 – Next-generation TCR-T

Building on First-Gen IMA203 Success to Further Improve Anti-Tumor Activity





- Engagement of CD4 T cells by CD8 co-transduction reported to boost anti-tumor activity in TCR-T trials
- Recent data from leukaemia patients treated with CAR-T achieving decade-long remissions show that CD4 T cells dominate at the later time points of response¹
- Functional superiority of the **CD8αβ** construct over multiple other CD8 constructs in preclinical experiments
- Proprietary 4-in-1 lentiviral vector to engineer CD4 and CD8 T cells with the PRAME-specific IMA203 TCR and CD8αβ construct (IMA203CD8)

Co-Transduction of CD8 Enhances Anti-Tumor Activity in Vitro

3D Spheroid Killing – CD4 T cells

No CD4 IMA203 IMA203CD8 2.0 T cells TCR TCR IMA203CD8 TCR IMA203 TCR Non-Transduced Control Day 0 1.5 2nd addition 3rd addition **Tumor Growth** of tumor cells of tumor cells 1.0 Day 3 0.5 Dav 0.0 18 36 56 74 94 114 134 152 172 192 Hours after co-culture

Serial Killing Assay - CD8 & CD4 T cells

Engagement of CD4 T cells may enhance depth and durability of anti-tumor response and clinical outcome of TCR-T in solid cancer patients

IMA203CD8 Full Data Presentation at SITC 2021: Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression





ACTengine[®] IMA201 and IMA204 - TCR-T Targeting MAGEA4/8 and COL6A3

ACTengine[®] IMA201 Targeting MAGEA4/8

r cell, app

Key Features

spectrometry platform

Immatics

TARGET	TCR	CLINICAL DATA	PATIENT POPULATION ³
HLA-A*02-presented peptide derived from MAGEA4 and/or MAGEA/8 >5-fold higher peptide copy number per tumor cell than a commonly used MAGEA4 target Naturally and specifically presented on tumors at high target density ¹ : 100-1,000 copies/cell Identified and validated by	High-affinity, specific TCR targeting MAGE4/8 High functional avidity ² : EC50 ~10 ng/ml Identified and characterized by XCEPTOR® TCR discovery and engineering platform	Dose escalation ongoing, target dose level to commence Too early for assessment of safety or anti-tumor activity	Sarcoma Subtypes – up to 80% Squamous NSCLC – 50% HNSCC – 35% Bladder Carcinoma – 30% Esophageal Carcinoma – 25% Uterine Carcinosarcoma – 25% Ovarian Carcinoma – 20% Melanoma – 20%

Status – 02-June-2022

ACTengine[®] IMA204 First-in-Class TCR-T Targeting Tumor Stroma Key Features

immatics


TARGET	TCR	PRECLINICAL DATA	PATIENT POPULATION ³
HLA-A*02-presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density ¹ : 100-700 copies/cell Novel tumor stroma target identified and validated by XPRESIDENT® quant. mass spectrometry platform	High-affinity, specific TCR targeting COL6A3 exon 6 Affinity-maturated, CD8-independent TCR High functional avidity ² : ~0.01ng/ml Identified and characterized by XCEPTOR® TCR discovery and engineering platform	CD8-independent, next- generation TCR engages both, CD8 and CD4 T cells <i>In vitro</i> anti-tumor activity against target-positive cell lines in CD8 and CD4 T cells Complete tumor eradication in <i>in vivo</i> mouse models	Pancreatic Carcinoma – 80% Breast Carcinoma – 75% Stomach Carcinoma – 65% Sarcoma – 65% Esophageal Carcinoma – 60% Squamous NSCLC– 55% Adeno NSCLC– 55% HNSCC – 55% Uterine Carcinosarcoma – 559 Colorectal Carcinoma – 45% Mesothelioma – 45% Cholangiocarcinoma – 40% Ovarian Carcinoma – 40% Melanoma – 35% Bladder Carcinoma – 35%

IMA204 provides a promising therapeutic opportunity for a broad patient population as monotherapy or in combination with TCR-T cells directed against tumor targets


¹ Target density: peptide copy number per tumor cell, approximate range representing the majority of tumor samples analyzed; ² Functional avidity: EC50 half maximal effective concentration; ³ Solid cancer indications with 20% or more target expression. Target prevalence for selected cancer indications based on mRNA expression (TCGA and Immatics inhouse data).

ACTengine® IMA204 – High Affinity, CD8-independent TCR

Complete Tumor Eradication in vitro & in vivo¹ by Affinity-enhanced IMA204 TCR



in tumor stroma across many solid cancers



- Affinity maturated CD8-independent, next-generation TCR engages both CD4 and CD8 T cells without the need of CD8 co-transduction
- IND-enabling studies are nearing completion

IMA204 ¹ In vivo data in collaboration with Jim Riley, University of Pennsylvania, control: non-transduced T cells. TCR avidity and specificity data not shown, available in IMA204 presentation on Immatics website. 28








ACTallo® – Our Next-generation Off-the-shelf TCR-T

ACTallo® – Immatics' Allogeneic Cell Therapy Approach

immatics



- Off-the-shelf cell therapy, no need for personalized manufacturing \rightarrow reduced logistics and time to application
- Potential for hundreds of doses from one single donor leukapheresis \rightarrow lower cost of goods
- Use of healthy donor material provides standardized quality and quantity of starting material




Why $\gamma\delta$ T cells? $\gamma\delta$ T cells Are Well Suited for an Off-the-shelf Cell Therapy Approach

γδ T cells

- ✓ are abundant in the peripheral blood
- ✓ show intrinsic anti-tumor activity
- naturally infiltrate solid tumors & correlate with favorable prognosis
- are HLA-independent, thus do not cause graft-vs-host disease in allogeneic setting
- can be expanded to high numbers in a cGMP-compatible manner
- can be effectively redirected using αβ TCR or CAR constructs








TCER® – TCR Bispecifics




TCER[®] – Mechanism of Action

Immatics' Off-the-Shelf TCR Bispecifics Approach



TCER®

TCER® – Immatics' Half-Life Extended Bispecifics



pHLA targeting TCR

- ✓ High-affinity TCR targeting HLA-restricted tumor-specific peptides
- ✓ Broad therapeutic window through XPRESIDENT[®]-guided affinity maturation (>1000x)¹

immatics

✓ Complete tumor eradication in mouse xenograft models at low doses

T cell recruiting antibody

- ✓ Low-affinity T cell recruiter against both TCR & CD3
- ✓ Optimized biodistribution aiming for enrichment at tumor site and prevention of CRS²
- ✓ Superior anti-tumor activity in mouse models as compared to widely used CD3 recruiters

Next-generation TCER® format


- ✓ Off-the-shelf biologic with antibody-like manufacturability³ and low cost of goods
- ✓ Superior anti-tumor activity⁴ compared to six alternative bispecific formats
- ✓ Half-life of several days expected in humans

Our TCER® format is designed to maximize efficacy while minimizing toxicities in patients

TCER® ¹ As compared to natural TCR; ² Based on literature data for other low-affinity recruiters (e.g. Harber *et al.*, 2021, Nature); ³ Production in mammalian cells (CHO cells); ⁴Based on preclinical testing

Potency of Our Proprietary TCR Bispecific Format TCER®





- Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody
- TCER® format had higher combination of potency and specificity¹ than six alternative TCR Bispecific format designs evaluated Flexible Plug-and-play platform: TCER® format successfully validated for different TCRs & different T cell recruiting antibodies

TCER[®] ¹ Preclinical data on specificty not shown

TCER[®] Portfolio

Building a Pipeline of Next-Gen Half-Life Extended TCR Bispecifics



	IMA401	IMA402	IMA40X
	MAGEA4/8	PRAME	Undisclosed
Status	Start of Phase 1 trial in May 2022	Clinical GMP batch targeted in 2022 Phase 1 trial in 2023	TCER [®] engineering and preclinical testing ongoing
Preclincial Proof-of-concept - Efficacy / Safety	Complete remission of estab. tumors in xenograft mouse models at low doses n/a Very broad therapeutic window (reactivity tumor compared to normal cells) Half-life extended to several days via effector function silenced Fc part First-in-human basket trial Adaptive design aiming at fast dose escalation Development strategy includes TCER® as add on to		
Half-life			
Clinical Development Strategy			

TCER®

Phase 1 Clinical Trial to Evaluate TCER® IMA401 Targeting MAGEA4/8


TCER®





Phase 1 Clinical Trial to Evaluate TCER® IMA401 Targeting MAGEA4/8






who is maximum tolerated dose, wire to recommended phase 2 dose, whole, minimum anticipated biological effect (ver, betwire bayesian logistic regression model)
¹ Pharmacokinetics data assessed throughout the trial might provide an opportunity to optimize scheduling to a less frequent regimen. ² Conducted in collaboration with B

TCER®

38

TCER® IMA401 Targeting MAGEA4/8

Product Candidate in Clinical Development with Bristol Myers Squibb



- Complete remissions observed in all animals even at low IMA401 dose of 0.05 mg/kg
- No detectable outgrowth of tumors during prolonged observation period of 70 days

TCER®	¹ Hs695T xenograft model in MHC I/II ko NSG mice, tumor volume of individual mice shown
-------	--

TCER® IMA402 Targeting PRAME

Preclinical-stage Product Candidate Fully Owned by Immatics



PRAME Target Peptide

- HLA-A*02-restricted PRAME peptide targeted by TCER[®] IMA402 is one of the most frequently expressed intracellular cancer targets for TCR-based therapies
 - Homogenously expressed at high prevalence across multiple solid tumors including melanoma, lung cancer, gynecological cancers (ovarian, breast, uterine) and others

Preclinical Proof-of-Concept Data

- High in vitro potency in killing of tumor cells with physiological PRAME peptide levels
- · Favorable safety profile with broad therapeutic window between tumor and normal cell reactivity in vitro
- · Consistent tumor regression including complete responses in NOG mice treated at low doses
- Extended serum half-life of several days¹ expected in humans driven by the TCER[®] Fc part

Well Progressing CMC Development


- · Current data support antibody-like manufacturability and developability
- GMP process development and IND-enabling activities ongoing
- Manufacturing of the clinical batch for the Phase 1 trial expected in 2H 2022

TCER[®] ¹ Based on preclinical testing

0

TCER® IMA402 – Efficacy Assessment in Tumor Model in Mice

Superior Tumor Control Using a Proprietary, Low-Affinity Recruiter




Proprietary, **low-affinity T cell recruiting region** demonstrates superior tumor control compared to analogous TCER[®] molecules designed with higher-affinity variants of a widely used recruiter





TCER® IMA402 - In vitro Safety Assessment with Normal Tissue Cells



Normal Tissue Type	Therapeutic Window (x-fold)
IPSC-derived astrocytes	≥1,000
IPSC-derived GABA neurons	≥1,000
IPSC-derived cardiomyocytes	≥1,000
Human Pulmonary Fibroblasts	≥1,000
Human Cardiac Microvascular Endothelial Cells	≥1,000
Human Dermal Microvascular Endothelial Cells	≥1,000
Human Aortic Endothelial Cells	≥1,000
Human Coronary Artery Smooth Muscle Cells	≥1,000
Human Tracheal Smooth Muscle Cells	≥1,000

- Cytotoxicity against N≥9 different human normal tissue cell types
- TCER[®] IMA402 shows a <u>minimum of 1,000-fold therapeutic window</u> between normal tissue cell reactivity and tumor cell reactivity

42

immatics



Immatics' Proprietary Target and TCR Discovery Platforms


True Cancer Targets & Matching Right TCRs

Goal to Maximize Anti-Tumor Activity and Minimize Safety Risks of TCR-based Immunotherapies



True Targets via XPRESIDENT® technology platform

- are naturally presented on tumor tissues as identified by mass-spec ٠
- are absent or presented at only low levels on normal tissues .
- are presented at high copy numbers to trigger a pharmacological response




Right TCRs via XCEPTOR® technology platform

- recognize the target peptide with high affinity and specificity •
- show selective killing of tumor cells
- are developed to be suitable for two different therapeutic modalities, Cell Therapies and TCR Bispecifics

Technology




Immatics' Unique Capability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target




Pool of 200 Prioritized Targets as Foundation for Future Value Generation





Development of the Right TCR – XCEPTOR® Technology

TCR Discovery and Engineering for ACT and TCR Bispecifics



- Fast, efficient and highly sensitive discovery of highly specific, natural TCRs
- · Protein engineering capabilities to design and maturate TCRs with increased affinity while retaining specificity
- Early de-selection of cross-reactive TCRs by the unique interplay between Immatics' target and TCR discovery platforms XPRESIDENT[®] and XCEPTOR[®] during TCR discovery¹ and TCR maturation²


Technology ¹XPRESIDENT[®]-guided off-target toxicity screening; ² XPRESIDENT[®]-guided similar peptide counterselecti

immatics

Optimal Target Selection & TCR Specificity for Minimizing Safety Risks



Unique Interplay between Technology Platforms Allows Early De-risking for Clinical Development



Technology ¹Clinical fatalities have occurred in TCR-T trials using a titin cross-reactive TCR (Cameron *et al.*, Sci Transl Med)





Corporate Information & Milestones

Experienced Global Leadership Team Across Europe and the US





Harpreet Singh Chief Executive Officer Co-Founder >20 yrs biotech experience



Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience (Micromet, Roche, Fresenius)



Rainer Kramer Chief Business Officer 25 yrs pharma & biotech experience (Amgen, MorphoSys, Jerini, Shire,

Signature Dx)



Arnd Christ Chief Financial Officer >20 yrs biotech experience (Probiodrug, NovImmune, Medigene, InflaRx)



Steffen Walter Chief Technology Officer Co-Founder Immatics US >15 yrs biotech experience



Edward Sturchio General Counsel >15 yrs pharma & biotech experience (Schering, Merck, Novartis, Advanced Accelerator Applications, Abeona Therapeutics)



Cedrik Britten Chief Medical Officer >10 yrs pharma & biotech experience (BioNTech, GSK)



Toni Weinschenk Chief Innovation Officer Co-Founder >15 yrs biotech experience



Jordan Silverstein Head of Strategy >10 yrs biotech experience (Advanced Accelerator Applications, InflaRx)

Strong, Focused and Highly Integrated Trans-Atlantic Organization







Tübingen, Germany, ~195 FTEs Target & TCR discovery and TCR Bispecifics development




Houston, Texas, ~140 FTEs Cell therapy development and manufacturing



Munich, Germany, ~55 FTEs Various operating functions


Robust IP Portfolio

Immatics' Patent Estate – Territorial Coverage



Near-Term Value Drivers and Development Milestones

Clinical Expansion of TCR Bispecifics and the Next-generation of TCR-T



immatics



www.immatics.com

